NCT01387711View on ClinicalTrials.gov

PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Histology

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Actinic Keratosis
Interventions
DRUG

PEP005 (Ingenol mebutat Gel, 0.05 %)

All eligible patients will receive PEP005 Gel, 0.05 %, on two consecutive days to both the AK Treatment Area and the Normal Skin Treatment Area

Trial Locations (1)

D-37075

Universitätsmedizin Göttingen, Georg-August-Universität, Göttingen

Sponsors

Lead Sponsor

LEO Pharma
All Listed Sponsors
lead

LEO Pharma

INDUSTRY